World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
39586
World Ranking
7358
National Ranking
3853

Overview

David Schiff is affiliated with the University of Virginia in the United States. Their research focuses primarily on the field of Medicine, with notable contributions in subfields such as Genetics, Radiology, Nuclear Medicine and Imaging, Neurology, Pulmonary and Respiratory Medicine, and Oncology.

Their main research topics include:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Neuroblastoma Research and Treatments
  • Meningioma and schwannoma management
  • Cancer Genomics and Diagnostics
  • Neurofibromatosis and Schwannoma Cases

David Schiff has published extensively, with research appearing frequently in the following venues:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • Journal of Neuro-Oncology
  • Neuro-Oncology Advances
  • Neuro-Oncology Practice

Among the recent papers authored in collaboration with others, notable publications include:

  • "Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions," 2020, Neuro-Oncology
  • "Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline," 2021, Journal of Clinical Oncology
  • "Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions," 2022, Neuro-Oncology
  • "Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma," 2023, Journal of Clinical Oncology
  • "SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors," 2021, Neuro-Oncology

Frequent coauthors in their work have included:

  • Patrick Y. Wen
  • Andrew B. Lassman
  • David A. Reardon
  • Evanthia Galanis
  • Martin J. van den Bent

Best Publications

  • A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

    Mark R. Gilbert;James J. Dignam;Terri S. Armstrong;Terri S. Armstrong;Jeffrey Scott Wefel

  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

    Henry S. Friedman;Michael D. Prados;Patrick Y. Wen;Tom Mikkelsen

  • Law as a Social System

    Niklas Luhmann;Klaus A. Ziegert;Fatima Kastner;Richard Nobles

  • NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

    Roger Stupp;Eric T. Wong;Andrew A. Kanner;David Steinberg

  • Response assessment criteria for brain metastases: proposal from the RANO group

    Nancy U Lin;Eudocia Q Lee;Hidefumi Aoyama;Igor J Barani

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Patrick Y. Wen;Michael Weller;Eudocia Quant Lee;Brian M. Alexander

  • microRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes

    Yunqing Li;Fadila Guessous;Ying Zhang;Charles DiPierro

  • Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review

    Leland Rogers;Igor Barani;Marc Chamberlain;Thomas J. Kaley

  • Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

    M. J. van den Bent;J. S. Wefel;D. Schiff;M. J. B. Taphoorn

  • Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

    David A. Reardon;Karen L. Fink;Tom Mikkelsen;Timothy F. Cloughesy

  • Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome

    Patrick G. Morris;Denise D. Correa;Joachim Yahalom;Jeffrey J. Raizer

  • Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma

    Gaurav D. Shah;Joachim Yahalom;Denise D. Correa;Rose K. Lai

  • Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

    Patrick Y. Wen;W. K Alfred Yung;Kathleen R. Lamborn;Patricia L. Dahia

  • Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

    Susan M. Chang;Patrick Wen;Timothy Cloughesy;Harry Greenberg

  • Malignant spinal-cord compression

    Dheerendra Prasad;David Schiff

  • The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.

    Janet E. Olson;Carol A. Janney;Ravi D. Rao;James R. Cerhan

  • microRNA-34a is tumor suppressive in brain tumors and glioma stem cells

    Fadila Guessous;Ying Zhang;Alexander Kofman;Alessia Catania

  • Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.

    Sigal Grisariu;Batia Avni;Tracy T. Batchelor;Martin J. van den Bent

  • Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American brain tumor consortium study

    Michael D. Prados;W. K.A. Yung;Kurt A. Jaeckle;H. Ian Robins

  • Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

    Paul D. Brown;Sunil Krishnan;Jann N. Sarkaria;Wenting Wu

Frequent Co-Authors

Patrick Y. Wen
Patrick Y. Wen Harvard University
David A. Reardon
David A. Reardon Harvard University
Tracy T. Batchelor
Tracy T. Batchelor Brigham and Women's Hospital
Timothy F. Cloughesy
Timothy F. Cloughesy University of California, Los Angeles
Keith L. Ligon
Keith L. Ligon Harvard University
Lauren E. Abrey
Lauren E. Abrey University of Zurich
Susan M. Chang
Susan M. Chang University of California, San Francisco
Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
Michael A. Vogelbaum
Michael A. Vogelbaum Cleveland Clinic
Lisa M. DeAngelis
Lisa M. DeAngelis Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Medicine but seeking alternative or complementary career paths, there are many online degree options in health and healthcare administration. An online healthcare administration degree provides essential management skills and health system knowledge, offering a pathway to administrative roles in hospitals and clinics.

Those looking for advanced leadership opportunities can consider the cheapest online mha programs to earn a Master’s in Healthcare Administration (MHA) at an affordable cost. This degree can fast-track your career in health services management and hospital administration.

For practicing nurses, the best online dnp programs allow for the highest level of clinical training and leadership within nursing, further expanding professional opportunities and expertise.

If pharmacy is your focus, exploring an online pharmd program can prepare you to become a licensed pharmacist while offering the flexibility of remote study.

These online degrees provide accessible routes into high-demand healthcare fields, each with strong career growth potential and the flexibility suited for working adults and career changers.

Best Scientists Citing David Schiff

Trending Scientists